Literature DB >> 8150751

beta-Lactam resistance amongst Enterobacter species.

A F Ehrhardt1, C C Sanders.   

Abstract

Following the introduction of extended-spectrum cephalosporins into clinical use, the prevalence of species belonging to the genus Enterobacter has increased because of their natural resistance to earlier cephalosporins and their ability to develop resistance rapidly to the newer drugs. beta-Lactam resistance in this genus is due, for the most part, to the presence of a Bush group 1 chromosomal cephalosporinase. This enzyme is normally inducible and resistance to older cephalosporins, cephamycins and aminopenicillins results from either the extreme lability of the drugs to the enzyme or from their inducer activities. Resistance to newer penicillins, cephalosporins and monobactams is attributable to the selection of mutants which express large amounts of the enzyme. Such mutants arise as the result of a spontaneous mutation in one of the regulatory genes responsible for suppressing enzyme expression. Since the enzyme has very high affinity for the newer cephalosporins, this, coupled with the slow penetration of the drugs into the cell, provides a very efficient mechanism of resistance. Recent surveys in the USA and elsewhere have shown that the increased prevalence of multi-beta-lactam-resistant strains of enterobacter is due to the increased use of the newer cephalosporins. Attempts to prevent these problems include the more judicious use of newer beta-lactam antibiotics and the development of enhanced-potency cephalosporins which are able to avoid resistance because they have lower enzyme affinity and permeate more rapidly into the cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8150751     DOI: 10.1093/jac/32.suppl_b.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Extended-spectrum beta-lactamase enzymes in clinical isolates of Enterobacter species from Lagos, Nigeria.

Authors:  I E Aibinu; V C Ohaegbulam; E A Adenipekun; F T Ogunsola; T O Odugbemi; B J Mee
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  Epidemiology of infections due to multiresistant Enterobacter aerogenes in a university hospital.

Authors:  F Allerberger; T Koeuth; C Lass-FLörl; M P Dierich; C Putensen; E Scmutzhard; I Mohsenipour; H Grundmann; D Hartung; A Bauernfeind; E Eberlein; J R Lupski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

3.  Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.

Authors:  R N Charrel; J M Pagès; P De Micco; M Mallea
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 4.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.

Authors:  J Martínez-Beltrán; R Cantón; J Liñares; J García de Lomas; C Gimeno; F Tubau; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

6.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  In vitro antibacterial activity of Ibuprofen and acetaminophen.

Authors:  Ali Abdul Hussein S Al-Janabi
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 9.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 10.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.